What is HC Wainwright’s Estimate for CGTX FY2024 Earnings?

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Investment analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Cognition Therapeutics in a research note issued to investors on Wednesday, November 27th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.87) for the year, down from their previous forecast of ($0.72). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Cognition Therapeutics’ Q4 2024 earnings at ($0.19) EPS and FY2025 earnings at ($0.31) EPS.

CGTX has been the topic of a number of other research reports. Chardan Capital reaffirmed a “buy” rating and set a $11.00 price target on shares of Cognition Therapeutics in a research report on Friday, November 15th. B. Riley reaffirmed a “neutral” rating and set a $1.00 price objective (down from $5.00) on shares of Cognition Therapeutics in a report on Tuesday, August 6th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Cognition Therapeutics Trading Down 0.5 %

Shares of NASDAQ CGTX opened at $0.40 on Monday. The stock has a fifty day simple moving average of $0.47 and a two-hundred day simple moving average of $1.09. Cognition Therapeutics has a 1-year low of $0.34 and a 1-year high of $2.95. The firm has a market cap of $16.62 million, a price-to-earnings ratio of -0.41 and a beta of 1.34.

Institutional Trading of Cognition Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CGTX. Virtu Financial LLC bought a new position in Cognition Therapeutics in the 3rd quarter worth about $27,000. Bangor Savings Bank boosted its position in shares of Cognition Therapeutics by 41.6% in the second quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock valued at $56,000 after acquiring an additional 10,000 shares during the period. Sigma Planning Corp grew its stake in Cognition Therapeutics by 14.6% during the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after acquiring an additional 25,050 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its holdings in Cognition Therapeutics by 33.4% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock worth $159,000 after acquiring an additional 24,050 shares during the period. Finally, CM Management LLC increased its holdings in Cognition Therapeutics by 14.3% during the 2nd quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after acquiring an additional 25,000 shares during the period. 43.35% of the stock is currently owned by institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.